Search clinical trials for: Recombinant human antithrombin (rhAT)

Total 1285 results

rEVO Biologics

Completed

Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)

Preeclampsia

United States
rEVO Biologics

Completed

Recombinant Human Antithrombin (rhAT) in Patients With Hereditary Antithrombin Deficiency Undergoing Surgery or Delivery

Antithrombin III Deficiency

United States, France, United Kingdom, Germany, Canada, Austria, Australia, Italy
rEVO Biologics

Completed

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations. (rhAT)

Antithrombin Deficiency, Congenital

France, United Kingdom, Germany, United States, Sweden, Italy
Mayo Clinic
rEVO Biologics

Terminated

Response of Recombinant Antithrombin in Heparin Resistant Patients Undergoing Cardiac Surgery

Thrombophilia Due to Acquired Antithrombin III Deficiency

United States
Merck Sharp & Dohme LLC

Completed

Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038)

Measles | Rubella | Mumps | Varicella
Medical College of Wisconsin
Children's National Research Institute; rEVO Biologics

Terminated

Antithrombin III Supplementation for Cardiopulmonary Bypass in Neonates

Postoperative Hemorrhage

United States
Protein Sciences Corporation

Completed

Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults

Influenza

United States
Shandong University
Shandong Provincial Hospital; The First Affiliated Hospital of Dalian Medical...

Completed

An Investigation of rhTPO With Different Frequencies in the Management of ITP

Immune Thrombocytopenia

China
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011)

Measles | Mumps | Varicella

France, Germany
Seoul National University Hospital

Active, not recruiting

Antithrombin-III for Patients With Hepatic Veno-occlusive Diseases Following Hematopoietic Stem Cell Transplantation

Hepatic Veno-Occlusive Disease

Korea, Republic of
Peking Union Medical College
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

Efficacy and Safety Study of Maintenance Treatment With rhTPO in Thrombocytopenic Subjects With ITP

Thrombocytopenia | Immune Thrombocytopenia | Idiopathic Thrombocytopenic Purpura

China
Massachusetts General Hospital

Completed

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
Tianjin Medical University General Hospital

Unknown

Efficacy and Safety of Thrombopoietin In Patients With Severe and Very Severe Aplastic Anemia

Anemia, Aplastic

China
Seoul National University Hospital

Completed

Antithrombin III Concentrate After Liver Transplantation

Liver Transplant; Complications

Korea, Republic of
Children's Hospital Los Angeles

Withdrawn

Pharmacokinetic Study of Recombinant AT III in Neonates Undergoing ECMO

Neonates on ECMO

United States
Steen Bonnema

Completed

rhTSH, Radioiodine Uptake and Goiter Reduction Following 131I Therapy in Patients With Benign Nontoxic Nodular Goiter

Nodular Goiter

Denmark
Grace Science, LLC

Recruiting

Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

NGLY1 Deficiency

United States
The First Hospital of Jilin University

Completed

Phase II/III of Recombinant Human Albumin Injection

Hepatic Ascites

China
Protein Sciences Corporation

Completed

Comparison of the Immunogenicity, Safety and Reactogenicity of FluBlok, To a Licensed Vaccine In Elderly Adults

Influenza

United States
Massachusetts General Hospital

Withdrawn

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
Hongnan Mo

Unknown

Recombinant Human Thrombopoietin for Mobilization of Peripheral Blood Progenitor Cells for Autologous Transplantation

Hematopoietic Stem Cell Transplantation | Thrombocytopoietin | Hematopoietic Stem Cell Mobilization

China
Massachusetts General Hospital

Completed

The Safety and Efficacy of Recombinant Human Prolactin

Healthy

United States
Massachusetts General Hospital

Completed

Recombinant Human Prolactin for Lactation Induction

Lactation

United States
University of Milan
Eli Lilly and Company

Unknown

Evaluation of rhGH Replacement Therapy in Patients With Pseudohypoparathyroidism Type Ia (PHP Ia)

Growth Hormone Deficiency, Dwarfism | Pseudohypoparathyroidism

Italy
Protein Sciences Corporation

Completed

Immunogenicity and Safety of FluBlok Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Pediatrics

Influenza

United States
Protgen Ltd

Completed

Phase II/III of Recombinant Human Serum Albumin

Hepatic Ascites

China
Protgen Ltd

Completed

Recombinant Human Serum Albumin in Healthy Subjects

Hepatic Ascites

China
Octapharma

Not yet recruiting

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

Acquired Antithrombin Deficiency
The First Hospital of Jilin University

Completed

Phase Ib of Recombinant Human Albumin Injection

Ascites

China
Shandong University
The First Affiliated Hospital of Anhui Medical University; The Affiliated Hospital... and other collaborators

Completed

rhTPO Combining Rituximab Versus Low-dose Rituximab in Management of ITP

Purpura | Idiopathic Thrombocytopenic Purpura

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment

Liver Cirrhosis

China
Nanfang Hospital of Southern Medical University
First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People... and other collaborators

Unknown

Efficacy and Safety of rHuTPO on Platelet Engraftment After Allo-HSCT (TPO)

Allogeneic Hematopoietic Stem Cell Transplantation | Myeloablative | Delayed Platelet Engraftment

China
Institute of Hematology & Blood Diseases Hospital

Completed

Efficacy and Safety of rhTPO for the Treatment of Thrombocytopenia After Chemotherapy in AML Patients

Thrombocytopenia

China
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Study of Subcutaneous Hydration Enabled by Human Recombinant Hyaluronidase (Hylenex) (INFUSE-NSLR)

Healthy

United States
Chinese Society of Lung Cancer

Terminated

Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

Carcinoma, Non-Small-Cell Lung

China
ZymoGenetics

Completed

Study of Interleukin-21 for Metastatic Malignant Melanoma and Metastatic Kidney Cancer

Melanoma | Kidney Neoplasms | Metastases

United States
National Cancer Institute (NCI)

Completed

Randomized Double-Blind Placebo-Controlled Trial Using Recombinant Human Interleukin-10 for Moderate-to-Severe Psoriasis

Psoriasis

United States
Chugai Pharmaceutical

Completed

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Chemotherapy Induced Anemia
Halozyme Therapeutics
Baxter Healthcare Corporation

Completed

Subcutaneous Rehydration Compared to Intravenous Rehydration (PEDs-II)

Dehydration

United States
Odense University Hospital

Completed

rhTSH, Thyroid Size, and Radioiodine Therapy in Benign Goiter

Graves' Disease | Benign Nontoxic and Toxic Goiter

Denmark
Grifols Therapeutics LLC
Covance; Clinipace Worldwide

Completed

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

Cardiac Surgery | Cardiopulmonary Bypass

United States
BioAegis Therapeutics Inc.

Completed

A Study to Evaluate Plasma Gelsolin in Healthy Volunteers

Healthy | Volunteers

United States
Novo Nordisk A/S

Completed

Incidence/Magnitude-Haemorrhagic Progression-Cerebral Contusions and Identification (ID) of Safety Issues After Traumatic Brain Injury

Trauma | Acquired Bleeding Disorder

United States, Canada
Novo Nordisk A/S

Completed

Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects

Healthy | Congenital Bleeding Disorder | Haemophilia A With Inhibitors | Haemophilia B With Inhibitors | Acquired Bleeding Disorder | Acquired Haemophilia | Congenital FVII Deficiency | Glanzmann's Disease

France
Novo Nordisk A/S

Completed

Recombinant Factor VIIa in Acute Intracerebral Haemorrhage

Acquired Bleeding Disorder | Intracerebral Haemorrhage

Spain, Sweden, Singapore, Norway, Italy, Switzerland, Australia, Austria, Belgium, Canada, Denmark, Finland, Germany, Netherlands, United Kingdom
Novo Nordisk A/S

Completed

Dose Response to Recombinant Factor VIIa When Administered for Bleed

Healthy | Congenital Bleeding Disorder

United States
Novo Nordisk A/S

Completed

Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State

Congenital Bleeding Disorder | Haemophilia A | Haemophilia B

France, Israel, Germany
Genzyme, a Sanofi Company

Completed

Tolerability and Safety Study of Recombinant Human Acid Sphingomyelinase in Acid Sphingomyelinase Deficiency Patients

Human Acid Sphingomyelinase Deficiency

United Kingdom, United States
Revimmune
Washington University School of Medicine

Terminated

Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease (IMPULSE-7)

Mycobacterium Infections, Nontuberculous

United States
Swedish Orphan Biovitrum

Completed

A Study to Assess the Safety and Tolerability of SOBI003 in Pediatric MPS IIIA Patients

Sanfilippo Syndrome Type A (MPS IIIA)

United States, Germany, Turkey

Search clinical trials for: Recombinant human antithrombin (rhAT)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations